Roche to invest $550 million in Indianapolis diagnostics hub expansion

Investing.com -- Roche (SIX:RO, ROG; OTCQX:RHHBY (OTC:RHHBY)) announced plans today to invest up to $550 million by 2030 into its Diagnostics site in Indianapolis. The site is set to become a major hub for the manufacturing of Roche’s continuous glucose monitoring (CGM) systems, marking a significant milestone in Roche’s history of healthcare innovation globally.

Indianapolis is the North American headquarters for Roche Diagnostics, a branch of the Roche Group, the world’s largest biotech company. This recent expansion emphasizes Roche’s dedication to advancing science, driving innovation, and providing cutting-edge solutions that enhance patient outcomes.

With over 38 million Americans currently living with diabetes, access to effective disease management solutions is vital. To meet this growing need, Roche is investing in a new CGM manufacturing facility in Indianapolis. CGM technologies provide crucial support for daily diabetes management, and this investment will further Roche’s mission to enhance patient care through innovation.

Brad Moore, President and CEO of Roche Diagnostics North America, stated, "The challenges of diabetes are pervasive, with millions of Americans living with the constant vigilance and countless daily decisions the disease requires. By expanding our manufacturing capabilities in Indianapolis, we ensure reliable access to innovative monitoring solutions for individuals living with diabetes in the U.S. and worldwide."

The Indianapolis campus includes key operations, such as U.S. research and development, laboratories, manufacturing, distribution, IT and administrative functions. It currently produces around 5.2 billion Accu-Chek® diabetes test strips annually and serves as one of two global distribution hubs, focusing on serving the U.S. market and supporting distribution to 53 countries worldwide.

This new commitment builds on more than $800 million in U.S. investments made at Roche U.S. sites since 2015, reinforcing Roche’s long-term commitment to U.S. operations and underlining the country’s central role in the company’s global strategy.

The expansion is anticipated to create hundreds of highly-skilled manufacturing jobs and thousands of construction jobs, providing a significant boost to Indiana’s economy. It will also improve domestic production capabilities and decrease dependency on imports, aligning with national efforts to bolster local manufacturing.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.